Yahoo · Aug 14, 2026
HeartBeam, Inc. Q2 2026 Earnings Call Summary
Moby summary of HeartBeam, Inc.'s Q2 2026 earnings call
NASDAQ · BEATW
HeartBeam, Inc.
Healthcare · Medical - Healthcare Information Services
$0.01
Up+$0.00 (+40.00%)
Updated Sep 20, 2026, 7:12 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 10.36M
- P/E ratio
- -3.54
- Dividend yield
- 0.00%
- 52-week range
- $0.01 – $0.18
- Volume
- 269
- Avg. volume
- 12.31K
Price performance
BEATW price history
1M range · 15 trading sessions · Daily adjusted prices
BEATW closed at $0.01 after 15 trading sessions, down 20.00% for the selected period.
- Last close
- $0.01
- Period change
- -20.00%
- Period low
- $0.01
- Period high
- $0.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $0.008 | $0.008 | $0.008 | $0.008 | 269 |
| Sep 16, 2026 | $0.008 | $0.008 | $0.008 | $0.008 | 3.01K |
| Sep 15, 2026 | $0.008 | $0.008 | $0.008 | $0.008 | 1.32K |
| Sep 14, 2026 | $0.0077 | $0.0078 | $0.0077 | $0.0077 | 5.55K |
| Sep 11, 2026 | $0.0147 | $0.0147 | $0.0075 | $0.0113 | 908 |
| Sep 10, 2026 | $0.0146 | $0.0146 | $0.011 | $0.011 | 406 |
| Sep 9, 2026 | $0.0075 | $0.0134 | $0.005 | $0.0134 | 74.91K |
| Sep 8, 2026 | $0.01 | $0.01 | $0.01 | $0.01 | 20.88K |
| Sep 2, 2026 | $0.0076 | $0.0117 | $0.0076 | $0.0117 | 37.76K |
| Sep 1, 2026 | $0.0147 | $0.0147 | $0.0103 | $0.0103 | 4.45K |
| Aug 31, 2026 | $0.009 | $0.009 | $0.009 | $0.009 | 15.91K |
| Aug 28, 2026 | $0.0101 | $0.0101 | $0.01 | $0.01 | 6.39K |
| Aug 27, 2026 | $0.0148 | $0.0148 | $0.0134 | $0.0148 | 2.39K |
| Aug 26, 2026 | $0.0119 | $0.0119 | $0.0119 | $0.0119 | 886 |
| Aug 25, 2026 | $0.011 | $0.011 | $0.0099 | $0.01 | 39.25K |
Latest BEATW news
The latest Smart Investors Daily articles mentioning BEATW.
Stock researchCompany · Overview
BEATW research
Overview
Company profile and research snapshot.
Company profile
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Yahoo · Aug 14, 2026
HeartBeam Inc (BEAT) (Q2 2026) Earnings Call Highlights: FDA Submission Advances and Commercial ...
HeartBeam Inc (BEAT) progresses its regulatory pathway with a 510(k) pre-submission while expanding commercial agreements and extending its cash runway into 2027.
SeekingAlpha · Aug 14, 2026
HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript
HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call August 13, 2026 4:30 PM EDTCompany ParticipantsRichard Ferrari - Executive ChairmanTimothy Cruickshank - Chief...
defenseworld.net · Dec 11, 2025
HeartBeam (NASDAQ:BEATW) Stock Price Up 73.7% – Here’s Why
HeartBeam, Inc. (NASDAQ: BEATW - Get Free Report) shot up 73.7% on Wednesday. The stock traded as high as $0.2170 and last traded at $0.2170. 159,985 shares traded hands during mid-day trading, an increase of 1,051% from the average session volume of 13,898 shares. The stock had previously closed at $0.1249. HeartBeam Stock Up 73.7%
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
